Kornberg Z, et al. - In men enrolled on active surveillance (AS) who undergo delayed radical prostatectomy (RP), researchers investigated if Genomic Prostate Score (GPS) was related to an increased risk of adverse pathology. This study included 215 men on AS with Gleason score (GS) 3+3 and GS 3+4 prostate cancer (PCa) who had GPS testing at diagnostic or confirmatory biopsy (ie within 1 year). Adverse pathology at delayed RP was considered as the primary outcome and was defined as GS ≥ 4+3, stage ≥ pT3a or pN1. Adjusting for Cancer of the Prostate Risk Assessment (CAPRA) score, the link between GPS and adverse pathology was assessed by using Cox proportional hazards regression, and inverse probability censored weights (IPCW) models. According to findings, an increased risk for adverse pathology on delayed RP was observed in relation to a higher GPS in patients who undergo RP after a relatively short period of AS.